Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Primary:
Define the maximal tolerated dose (MTD) of VNP40401M when given with hematopoietic cell
transplantation (HCT)
Secondary:
- Describe the change in pharmacokinetic (PK) parameters with increasing doses of drug.
- Describe and estimate the frequency of > Grade 3 non-hematologic/non-infectious
toxicities at the MTD.
- Report the efficacy of the regimen.
- Evaluate the rate of engraftment for the regimen.